figshare
Browse

Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children

Download (383.96 kB)
Version 2 2019-08-14, 15:37
Version 1 2019-07-17, 16:24
journal contribution
posted on 2019-08-14, 15:37 authored by Olubukola T. Idoko, Nuredin Mohammed, Patrick Ansah, Abraham Hodgson, Milagritos D. Tapia, Samba O. Sow, Paanchali R. Chowdhury, Matthias Niedrig, Elmar Saathoff, Beate Kampmann

Background: The World Health Organization recommends use of a single yellow fever (YF) vaccine dose for life and fractional doses in outbreaks when there are limited vaccine stocks. In endemic regions, this vaccine is given as part of routine infant immunization programs around 9 months of age. There is a need to better understand immune responses when vaccinating infants particularly in contexts where the child may be malnourished.

Methods: Data from 393 Malian and Ghanaian infants who concomitantly received measles and YF vaccines at 9 to 11 months of age were retrospectively analyzed. Response to YF vaccine was examined for association with nutritional status at time of vaccination, sex, age, pre-vaccination titers and season of vaccination.

Results: Neutralizing antibodies following vaccination were unaffected by season of vaccination, sex, pre-vaccination titers or nutritional status, though there was a trend to higher titers in males and children with higher height for age z-scores. Seroconversion rates differed significantly between countries (63.5 in Ghana vs. 91.0% in Mali).

Conclusion: Longitudinal, prospective studies are needed to optimize the use of YF vaccine in infants in endemic settings. There may be a need for booster vaccinations and to compare various vaccine preparations to optimize the use of available vaccines.

Funding

This work was funded by a Wellcome Trust Institutional Strategic Support Fund to Dr Olubukola Idoko (PS2874_WMNP) and Medical Research Council funding to Prof Beate Kampmann (MC_UP_A900/1122). The Program for Appropriate Technology in Health (PATH) funded the original trials, gave access to data for this analysis and reviewed manuscript drafts.

History

Usage metrics

    Expert Review of Vaccines

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC